-+ 0.00%
-+ 0.00%
-+ 0.00%
Vidac Pharma seeks partners for Phase 3 trial of VDA-1102 in actinic keratosis
Share
Listen to the news
Vidac Pharma seeks partners for Phase 3 trial of VDA-1102 in actinic keratosis
  • Vidac Pharma will seek partners for a Phase 3 trial of VDA-1102 targeting high-risk actinic keratosis lesions.
  • Previously reported Phase 2b results suggested treatment reduced abnormal skin-cell proliferation in highly proliferative lesions compared with placebo.
  • Treatment was well tolerated, with few significant local skin reactions.
  • The planned Phase 3 protocol will focus on lesions most likely to progress to cutaneous squamous cell carcinoma.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vidac Pharma Holding plc published the original content used to generate this news brief via pressetext (Ref. ID: 202611191010PRESSTXTEUPR____79B6FD681100FC834683F90DA3414AA) on November 19, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending